Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1159-1160

  Batla, Amit ^a   Stamelou, Maria ^a   Mencacci, Niccolo ^a,b   Schapira, Anthony H ^a   Bhatia, Kailash P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ROPINIROLE;

ADULT; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; LETTER; LIMB TREMOR; MONOTHERAPY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INDOLES; MIDDLE AGED; PARKINSON DISEASE;

EID: 84881551579     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25318     Document Type: Letter

References (9)

1. Rascol O, Brooks DJ, Korczyn AD, DeDeyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342:1484-1491.
2. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13:234-241.
3. Kumar N, VanGerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord. 2005;20:342-344.
4. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.
5. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology. 1998;51:1057-1062.
6. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22:2409-2417.
7. Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009;87:1-9.
8. Cannas A, Solla P, Floris G, et al. Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy. J Neurol. 2009;256:390-395.
9. Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol. 2004;185:36-46.